Related Tags >> Biogen Idec Elan multiple sclerosis FDA

Tysabri News

Most Popular Tysabri Story

Sources: Biogen gets bidders, with Pfizer in lead

November 8, 2007 — 6:59am ET

The Financial Times is reporting some tantalizing details about the bidding for Biogen Idec, the biotech based in Cambridge, MA, that Read more...

Tysabri Press Releases

Quest Diagnostics STRATIFY JCV(TM) 1st FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in MS patients
FDA Updates TYSABRI® (natalizumab) Label to Include Anti-JC Virus Antibody Status as a PML Risk Factor
Recent Multiple Sclerosis Market Events Have Resulted in Treatment Algorithm Modifications According to a Recent BioTrends
While Copaxone and Interferon-Betas Continue to Dominate Treatment in MS, Tysabri Shows Modest Increase in First-Line Use
Biogen Idec Promotes Tony Kingsley to Run Global Commercial Operations

Latest Headlines

$110M Acorda upfront takes a bite out of Biogen profits
July 16, 2009
Elan touts rising Tysabri sales as losses widen
April 22, 2009
Biogen Idec touts pipeline prospects in review
March 26, 2009
Icahn makes another play for Biogen control
February 6, 2009
More layoffs at GSK; Biogen: Tysabri patients have PML;
August 1, 2008
Icahn aims for Biogen control
January 29, 2008
FDA more friendly to approvable than approved
January 10, 2008
Biogen shares deflate as it gives up on sale
December 13, 2007
Biogen stock sinks as investors do reality check
November 14, 2007
Sources: Biogen gets bidders, with Pfizer in lead
November 8, 2007
Biogen Idec in play after Icahn makes his move
October 15, 2007
SPOTLIGHT: No new PML cases for Tysabri
October 12, 2007
Watchdog endorses use of Tysabri for severe MS
August 22, 2007
FDA committee backs Tysabri for Crohn's
August 1, 2007
After reintroduction, Tysabri builds patient base
July 23, 2007
ALSO NOTED: NPS sells facility; NICE backs Tysabri; Xolair gets black box warning;and much more...
July 2, 2007
New warning issued on Rituxan for lupus
December 18, 2006
ALSO NOTED: Elan, Biogen submit Tysabri for Crohn's; Affymax prices IPO;and much more...
December 14, 2006
Biogen Idec considering sale of cancer drug
October 31, 2006
Crohn's data indicates long-term Tysabri benefits
October 23, 2006

Paid Research Reports

More Research Reports >>